53Biologics

53Biologics is a Spanish contract development and manufacturing organization (CDMO) specializing in decoding biologics production, ranging from pDNA, mRNA to recombinant proteins. The company offers a range of services from preclinical and clinical development to GMP manufacturing, with a focus on supporting biopharma clients in bringing their biological products to market expeditiously. Notably, 53Biologics ensures high-quality standards and customer-centric services, including cell line development, cell banking, preclinical and clinical development, and contract manufacturing under various conditions - GMP, GMP Like, and non-GMP. Established in 2017, the company operates within the Biotechnology and Manufacturing industries from its headquarters in Spain. The latest development for 53Biologics was a noteworthy €7.00M Venture Round investment from Inveready and GAEA Inversión, finalized on 10 September 2021. For those interested, further information can be obtained by contacting the company directly.